TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced its CEO Bryan Kobel's upcoming participation in the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum.
The panel discussion is scheduled for February 27th, 2025, at 1:10 pm CET at the Hilton Zurich Airport Hotel. The forum, taking place on February 26-27, 2025, will feature over 12 hours of high-level keynotes and panel discussions, including HealthTech topics such as AI, convergence, and diagnostics.
The event will showcase more than 50 presentations from public, private, emerging, and seed companies seeking investment and partnering opportunities in innovative healthcare solutions.
TC BioPharm (NASDAQ: TCBP), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie con cellule T gamma-delta allogeniche per il cancro e altre condizioni, ha annunciato la partecipazione imminente del suo CEO Bryan Kobel al Cancer Progress Panel durante il 18° Forum Annuale dei CEO delle Scienze della Vita Europeo.
La discussione del panel è programmata per il 27 febbraio 2025, alle 13:10 CET presso l'Hotel Hilton Zurich Airport. Il forum, che si terrà il 26 e 27 febbraio 2025, presenterà oltre 12 ore di keynote e discussioni di alto livello, inclusi argomenti di HealthTech come l'IA, la convergenza e la diagnostica.
L'evento presenterà più di 50 presentazioni da aziende pubbliche, private, emergenti e seed che cercano opportunità di investimento e partenariato in soluzioni sanitarie innovative.
TC BioPharm (NASDAQ: TCBP), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias con células T gamma-delta alogénicas para el cáncer y otras condiciones, ha anunciado la próxima participación de su CEO Bryan Kobel en el Cancer Progress Panel en el 18º Foro Anual de CEOs de Ciencias de la Vida Europeo.
La discusión del panel está programada para el 27 de febrero de 2025, a la 1:10 pm CET en el Hilton Zurich Airport Hotel. El foro, que se llevará a cabo el 26 y 27 de febrero de 2025, contará con más de 12 horas de conferencias y discusiones de alto nivel, incluidos temas de HealthTech como IA, convergencia y diagnóstico.
El evento presentará más de 50 presentaciones de empresas públicas, privadas, emergentes y de capital semilla que buscan oportunidades de inversión y asociación en soluciones de atención médica innovadoras.
TC BioPharm (NASDAQ: TCBP)는 암 및 기타 질환을 위한 동종 감마 델타 T 세포 치료제를 개발하는 임상 단계의 생명공학 회사로, CEO인 브라이언 코벨이 암 발전 패널에 참여할 예정이라고 발표했습니다. 제18회 유럽 생명과학 CEO 포럼에서입니다.
패널 토론은 2025년 2월 27일 오후 1시 10분 CET에 취리히 공항 힐튼 호텔에서 예정되어 있습니다. 포럼은 2025년 2월 26일부터 27일까지 진행되며, AI, 융합, 진단과 같은 HealthTech 주제를 포함하여 12시간 이상의 고급 기조 강연 및 패널 토론이 진행될 예정입니다.
이 행사는 혁신적인 의료 솔루션에 대한 투자 및 파트너십 기회를 찾는 공공, 민간, 신생 및 시드 기업의 50개 이상의 발표를 선보일 것입니다.
TC BioPharm (NASDAQ: TCBP), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies par cellules T gamma-delta allogéniques pour le cancer et d'autres conditions, a annoncé la prochaine participation de son PDG Bryan Kobel au Cancer Progress Panel lors du 18ème Forum Annuel des PDG des Sciences de la Vie Européen.
La discussion du panel est prévue pour le 27 février 2025 à 13h10 CET à l'Hôtel Hilton Zurich Airport. Le forum, qui se déroulera les 26 et 27 février 2025, comprendra plus de 12 heures de discours d'ouverture et de discussions de haut niveau, y compris des sujets de HealthTech tels que l'IA, la convergence et le diagnostic.
L'événement présentera plus de 50 présentations d'entreprises publiques, privées, émergentes et en phase de démarrage à la recherche d'opportunités d'investissement et de partenariat dans des solutions de santé innovantes.
TC BioPharm (NASDAQ: TCBP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen Gamma-Delta-T-Zelltherapien für Krebs und andere Erkrankungen konzentriert, hat die bevorstehende Teilnahme seines CEO Bryan Kobel am Cancer Progress Panel beim 18. Jahrestreffen der CEOs der Lebenswissenschaften in Europa angekündigt.
Die Podiumsdiskussion ist für den 27. Februar 2025 um 13:10 Uhr CET im Hilton Zurich Airport Hotel angesetzt. Das Forum, das am 26. und 27. Februar 2025 stattfindet, wird über 12 Stunden hochrangiger Keynotes und Podiumsdiskussionen umfassen, einschließlich HealthTech-Themen wie KI, Konvergenz und Diagnostik.
Die Veranstaltung wird mehr als 50 Präsentationen von öffentlichen, privaten, aufstrebenden und Seed-Unternehmen präsentieren, die nach Investitions- und Partnerschaftsmöglichkeiten in innovativen Gesundheitslösungen suchen.
- None.
- None.
The forum will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF will feature more than 12 hours of high-level keynotes and panel discussions.
Additionally, there will be a global company showcase of 50+ presentations by established public, private, emerging, and seed companies, offering innovative solutions and seeking investment and partnering opportunities. For more information about the 18th Annual European Life Sciences CEO Forum, please click here.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum-302380543.html
SOURCE TC BioPharm
FAQ
When will TCBP CEO present at the European Life Sciences CEO Forum 2025?
What topics will be covered at the 2025 European Life Sciences CEO Forum where TCBP is presenting?
How many companies will be presenting at the 2025 European Life Sciences Forum alongside TCBP?
What is TCBP's current development focus in cancer treatment?
